Gene Mutation Provides Resistance to HIV Infection

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 9
Volume 5
Issue 9

NEW YORK--Scientists at the Aaron Diamond AIDS Research Center appear to have solved one of the long-standing enigmas of HIV infection--why some people remain uninfected even after repeated exposures to the virus. The answer lies in the genes, and in basic research published only a few months earlier.

NEW YORK--Scientists at the Aaron Diamond AIDS Research Centerappear to have solved one of the long-standing enigmas of HIVinfection--why some people remain uninfected even after repeatedexposures to the virus. The answer lies in the genes, and in basicresearch published only a few months earlier.

Studies of two homosexual men who have avoided infection sincethe start of the AIDS epidemic, despite having HIV-positive partners,uncovered a genetic mutation that appears to protect against infectionwith the virus. Both men were found to have two mutant copiesof the CCR5 gene (also known as CKR-5, or chemokine receptor-5),whose discovery was reported by five different groups in Junein a flurry of papers in Nature, Science, and Cell.

The CCR5 gene produces a protein receptor that allows HIV entryinto human immune cells. The two men with the mutant gene didnot have the receptor, Dr. Nathan R. Landau and his colleaguesreported in the journal Cell (August 9, 1996).

Other work suggests that as many as 1% of whites of Western Europeandescent may have the gene mutation, and up to 20% of whites mayhave one copy of the defective gene. Even one copy may have aprotective role, either in lowering the risk of infection or indelaying progression of HIV after infection.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content